Lifestyle and Metformin Interventions Show Significant Benefits in Diabetes Prevention

The Diabetes Prevention Program (DPP) enrolled 3,234 participants with impaired glucose tolerance (IGT) and fasting hyperglycemia, aiming to assess the effectiveness and cost-effectiveness of lifestyle and metformin interventions in preventing diabetes. Participants were randomized to receive either a lifestyle intervention, metformin, or placebo. The lifestyle intervention focused on achieving at least a 7% weight reduction through diet and physical activity, while metformin was administered at a dose of 850 mg twice daily after an initial month at 850 mg once daily.

Key Findings:

• Diabetes Incidence: At 10 years, the cumulative incidence of diabetes was significantly lower among lifestyle (26.5%) and metformin (41.5%) participants compared to placebo (52.4%).
• Quality of Life: Adherent lifestyle and metformin participants accrued more QALYs (6.80 and 6.74, respectively) than placebo participants (6.67).
• Cost-Effectiveness: From a health system perspective, lifestyle and metformin interventions were cost-saving relative to placebo. The cumulative undiscounted per participant cost of the lifestyle intervention was $4,810, compared to $2,934 for metformin and $768 for placebo.

Intervention Details:

• Lifestyle Intervention: Included a 16-session core curriculum, monthly follow-up visits, and group sessions aimed at reinforcing behavioral changes for weight loss and physical activity.
• Metformin Intervention: Participants were encouraged to continue metformin and participate in a group lifestyle intervention during the DPPOS maintenance phase.

Cost Analysis:

• The study calculated direct medical costs associated with the interventions and non-intervention-related medical care, finding that the costs of lifestyle and metformin were offset by the savings from reduced diabetes incidence and associated complications.
• The analysis also considered direct non-medical costs, including food, exercise, and transportation, from a societal perspective.

Conclusion: The findings underscore the effectiveness of lifestyle and metformin interventions in preventing diabetes among high-risk individuals. These interventions not only reduce the risk of diabetes but also improve quality of life and are cost-effective from a health system perspective. The study advocates for the adoption of these preventive measures in real-world clinical practice to mitigate the growing burden of diabetes.